China SXT Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2026, China SXT Pharmaceuticals, Inc. had total assets of $34.8m, total liabilities of $5.0m and shareholders' equity of $29.7m. It held $28.2m in cash against $999,565 of debt: net cash of $27.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

China SXT Pharmaceuticals, Inc.: balance sheet, annual
Fiscal year	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Cash and equivalents	0	1	9	7	13	16	17	12	18	28
Receivables	—	3	4	4	5	3	1	1	1	1
Inventory	—	1	1	1	1	1	1	1	1	1
Total current assets	—	6	16	20	23	22	20	14	21	35
Total assets	—	8	17	22	35	34	30	23	22	35
Accounts payable	—	2	2	2	1	1	1	1	1	0
Deferred revenue (current)	—	—	—	—	—	—	0	0	0	0
Total current liabilities	—	4	6	12	19	17	14	9	6	4
Short-term debt	—	—	0	0	0	0	0	0	0	0
Long-term debt	—	—	0	0	0	—	0	0	0	1
Total debt	0	0	0	7	0	0	0	0	0	1
Total liabilities	—	4	6	12	19	17	15	9	6	5
Shareholders' equity	2	3	11	9	16	16	15	14	15	30
Net debt (negative = net cash)	−0	−0	−9	−1	−13	−16	−17	−12	−18	−27

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: SXTC vs SXTP LPCN vs SXTC SCNX vs SXTC NTRB vs SXTC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China SXT Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to China SXT Pharmaceuticals, Inc.